{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T11:23:55Z","timestamp":1794828235511,"version":"4.9.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Aims:<\/jats:title>\n                    <jats:p>Neoadjuvant immunotherapy has emerged as the preferred treatment strategy for patients with resectable stage III melanoma. However, real-world data remain limited, especially regarding patients with in-transit metastasis (ITM). The aim of this study was to evaluate neoadjuvant immunotherapy in a population-based cohort of patients with stage III melanoma with a specific focus on patients with ITM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design:<\/jats:title>\n                    <jats:p>This population-based multicenter observational study included all patients with macroscopic stage III cutaneous melanoma treated with neoadjuvant PD-1 inhibitors at 5 academic cancer centers in Sweden from 2022 to 2025. Patients were stratified into 3 groups, LN metastasis only, ITM only, and concurrent LN and ITM involvement. The primary endpoint was major pathological response (MPR). Secondary endpoints included event-free survival (EFS), distant metastasis-free survival (DMFS), locoregional recurrence-free interval (LRFI), and safety outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 212 patients with a median follow-up of 14.7 months were included, of whom 41 had ITM only and 12 had both LN and ITM. The MPR rate was significantly higher in patients with LN metastases (52%) compared with ITM (22%) or concurrent LN and ITM (25%) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001). EFS and LRFI were significantly inferior in patients with ITM compared with LN metastases. In multivariable Cox regression analyses, ITM was associated with a higher risk of events for EFS (HR 2.00; 95% CI: 1.08\u20133.71;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.028) and LRFI (HR 4.41; 95% CI: 1.76\u201311.02;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.002). Although DMFS differed between groups in unadjusted analyses, no association was observed after multivariable adjustment (HR 1.04; 95% CI: 0.46\u20132.33;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.925).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>This study represents the largest real-world cohort specifically evaluating patients with ITM treated with neoadjuvant immunotherapy. The lower pathological response rate and inferior EFS observed in patients with ITM compared with LN metastases, together with an increased risk of locoregional recurrence, but no difference in DMFS, suggest that ITM may represent a biologically distinct disease phenotype with a higher propensity for locoregional treatment failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/sla.0000000000007177","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:00:33Z","timestamp":1785297633000},"page":"950-956","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Neoadjuvant Immunotherapy Using PD-1 Inhibitors for Resectable Stage III Cutaneous Melanoma \u2013 Different Outcomes Between Patients With Lymph Node and In-transit Metastases"],"prefix":"10.1097","volume":"284","author":[{"given":"Ellen","family":"Krabbe","sequence":"first","affiliation":[{"name":"Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Region V\u00e4stra G\u00f6taland, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Huibers","sequence":"additional","affiliation":[{"name":"Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Region V\u00e4stra G\u00f6taland, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Carneiro","sequence":"additional","affiliation":[{"name":"Department of Haematology, Oncology and Radiation Physics, Sk\u00e5ne University Hospital Comprehensive Cancer Center, Lund, Sweden"},{"name":"Department of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolin","family":"Isaksson","sequence":"additional","affiliation":[{"name":"Department of Surgery, Sk\u00e5ne University Hospital, Kristianstad, Sweden"},{"name":"Department of Clinical Sciences, Division of Surgery, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Bj\u00f6rkstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden"},{"name":"Theme Cancer, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Braslav","family":"Jovanovic","sequence":"additional","affiliation":[{"name":"Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden"},{"name":"Theme Cancer, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Valachis","sequence":"additional","affiliation":[{"name":"Department of Oncology, \u00d6rebro University Hospital, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustav J.","family":"Ullenhag","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden"},{"name":"Department of Oncology, Uppsala University Hospital, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildur","family":"Helgadottir","sequence":"additional","affiliation":[{"name":"Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden"},{"name":"Theme Cancer, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Ny","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden"},{"name":"Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden"},{"name":"Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5795-0355","authenticated-orcid":false,"given":"Roger","family":"Olofsson Bagge","sequence":"additional","affiliation":[{"name":"Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Region V\u00e4stra G\u00f6taland, Sweden"},{"name":"Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"R1-20261116","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"R2-20261116","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJMc1807505","article-title":"Adjuvant pembrolizumab in resected stage III melanoma","volume":"379","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"R3-20261116","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2159-8290.CD-21-1141","article-title":"Adjuvant pembrolizumab versus IFNalpha2b or ipilimumab in resected high-risk melanoma","volume":"12","author":"Grossmann","year":"2022","journal-title":"Cancer Discov"},{"key":"R4-20261116","doi-asserted-by":"crossref","first-page":"116201","DOI":"10.1016\/j.ejca.2025.116201","article-title":"Five-year survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study","volume":"234","author":"Helgadottir","year":"2026","journal-title":"Eur J Cancer"},{"key":"R5-20261116","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"key":"R6-20261116","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"key":"R7-20261116","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"R8-20261116","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"key":"R9-20261116","doi-asserted-by":"crossref","first-page":"290","DOI":"10.6004\/jnccn.2024.0036","article-title":"NCCN Guidelines(R) Insights: Melanoma: Cutaneous, Version 2.2024","volume":"22","author":"Swetter","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"R10-20261116","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Amaral","year":"2025","journal-title":"Ann Oncol"},{"key":"R11-20261116","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1245\/s10434-025-17084-4","article-title":"Identification of predictive factors for the development of in-transit metastasis in patients with melanoma","volume":"32","author":"Huibers","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"R12-20261116","doi-asserted-by":"crossref","first-page":"115485","DOI":"10.1016\/j.ejca.2025.115485","article-title":"Neoadjuvant immunotherapy for patients with resectable stage III\/IV cutaneous melanoma\u2014a Swedish retrospective real-world study (NEO-MEL)","volume":"224","author":"Nelson","year":"2025","journal-title":"Eur J Cancer"},{"key":"R13-20261116","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1245\/s10434-014-4100-0","article-title":"In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy","volume":"22","author":"Read","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"R14-20261116","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2022.03.041","article-title":"The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases\u2014a multicenter cohort study","volume":"169","author":"Holmberg","year":"2022","journal-title":"Eur J Cancer"},{"key":"R15-20261116","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2021.04.032","article-title":"Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases","volume":"152","author":"Zaremba","year":"2021","journal-title":"Eur J Cancer"},{"key":"R16-20261116","doi-asserted-by":"crossref","first-page":"e000440","DOI":"10.1136\/jitc-2019-000440","article-title":"Efficacy of immune checkpoint inhibitors for in-transit melanoma","volume":"8","author":"Nan Tie","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R17-20261116","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/CMR.0000000000000719","article-title":"The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials","volume":"31","author":"Olofsson Bagge","year":"2021","journal-title":"Melanoma Res"},{"key":"R18-20261116","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/bjd.18739","article-title":"Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease","volume":"183","author":"Weber","year":"2020","journal-title":"Br J Dermatol"},{"key":"R19-20261116","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejca.2021.02.012","article-title":"Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma","volume":"148","author":"Versluis","year":"2021","journal-title":"Eur J Cancer"},{"key":"R20-20261116","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","article-title":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","volume":"29","author":"Tetzlaff","year":"2018","journal-title":"Ann Oncol"},{"key":"R21-20261116","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R22-20261116","doi-asserted-by":"crossref","first-page":"e013564","DOI":"10.1136\/jitc-2025-013564","article-title":"Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma","volume":"13","author":"Yamada","year":"2025","journal-title":"J Immunother Cancer"},{"key":"R23-20261116","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1007\/s00262-020-02839-7","article-title":"T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model","volume":"70","author":"Stahlie","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"R24-20261116","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2340\/1651-226X.2026.45174","article-title":"SWE-NEO: Swedish NEO-adjuvant trial comparing anti-PD-1 monotherapy to combined anti-CTLA-4\/anti-PD-1 blockade in resectable stage III melanoma: study protocol for a phase III open-label multi-centre trial","volume":"65","author":"Helgadottir","year":"2026","journal-title":"Acta Oncol"}],"container-title":["Annals of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/SLA.0000000000007177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T11:00:37Z","timestamp":1794826837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/SLA.0000000000007177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/sla.0000000000007177","relation":{},"ISSN":["0003-4932","1528-1140"],"issn-type":[{"value":"0003-4932","type":"print"},{"value":"1528-1140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"2026-02-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}